Mayne Pharma Group Ltd. · ASX:MYX

Mayne Pharma — Merger or Acquisition (November 2026)

10 slides from Mayne Pharma's merger presentation, Nov 17, 2026

  1. Slide 1: Scheme Implementation Deed with Gedeon Richter

    rsonal use only Mayne Pharma Group Limited Scheme Implementation Deed with Gedeon Richter Aaron Gray (CEO) Griffin Buchanan (CFO) 17 November 2026

  2. Slide 2: Disclaimer

    Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the ASX announcement dated 17 November 2026 and rsonal use only the Scheme Implementation Deed attached to that announcement. This material is not intended

  3. Slide 3: Transaction Highlights

    Transaction Highlights1 Gedeon Richter2 to acquire 100% of Mayne Pharma by Scheme of Arrangement for A$6.40 per share in cash rsonal use only A$6.40 ~A$604m 99.4% Cash consideration Total equity value Premium to closing share per Mayne Pharma share3 for 100% of Mayne Pharma price on 16 Nov 2026 Marc

  4. Slide 4: Board Recommendation and Rationale

    Board Recommendation and Rationale The Mayne Pharma Board unanimously recommends that shareholders vote in favour of the Scheme¹ rsonal use only Significant premium, paid in cash • A$6.40 per share in cash, valuing Mayne Pharma’s equity at approximately A$604 million • 99.4% premium to the closing s

  5. Slide 5: About Gedeon Richter

    • Hungarian multinational pharmaceutical company, founded in 1901 and headquartered in Budapest; listed on Budapest Stock Exchange • Four business units: Women’s Healthcare (WHC), Neuropsychiatry (CNS), Biotechnology and General Medicines rsonal use only • FY251 total sales of EUR 2.34 billion at 31

  6. Slide 6: Conditions Precedent

    Conditions Precedent Regulatory rsonal use only • Foreign Investment Review Board (FIRB) approval • Clearance under the United States Hart-Scott-Rodino (HSR) Antitrust Improvements Act • No other orders or injunctions of a Court or Government Agency that would prevent the Scheme Shareholder and Cour

  7. Slide 7: Material Adverse Change Provisions

    Material Adverse Change Provisions No Mayne Pharma Material Adverse Change (MAC) is a condition precedent to the Scheme¹ rsonal use only Definition • A MAC requires a diminution in EBITDA of at least $12 million across the full financial year to 30 June 2027 or $12 million across FY28, measured agai

  8. Slide 8: Indicative Timetable and Next Steps

    Indicative Timetable and Next Steps Mayne Pharma shareholders do not need to take any action at this stage rsonal use only Event Expected date First Court Hearing Mid December 2026 Scheme Meeting Late January 2027 Second Court Date March 2027 Effective Date Mid to Late March 2027 Implementation Date

  9. Slide 9: Summary

    Summary • Following termination of the Scheme Implementation Deed with Cosette in December 2025, the Board initiated a structured rsonal use only review of the Company’s portfolio, including a sale process for Mayne Pharma International (A$55.5 million sale to Evaris Pharma announced to ASX on 6 Nov

  10. Slide 10: Q&A

    Q&A rsonal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Click here to view this Presentation on Investor Hub This presentation has been approved for release by the Board of Mayne Pharma You deserve tomorrow. 10

Mayne Pharma Group — Merger or Acquisition (November 2026) on 6ix